Anbio Biotechnology (NASDAQ:NNNN) Short Interest Down 44.9% in August

Anbio Biotechnology (NASDAQ:NNNN) was the target of a significant drop in short interest during the month of August. As of August 14th, there was short interest totaling 26,210 shares, a drop of 44.9% from the July 30th total of 47,525 shares. Based on an average trading volume of 49,980 shares, the short-interest ratio is currently 0.5 days. Approximately 0.0% of the company’s shares are sold short.

Analysts Set New Price Targets

Separately, Weiss Ratings lowered shares of Anbio Biotechnology from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Wednesday, July 29th. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, Anbio Biotechnology presently has an average rating of “Sell”.

Anbio Biotechnology Price Performance

Anbio Biotechnology stock traded down $0.15 during midday trading on Tuesday, reaching $7.15. The stock had a trading volume of 257,806 shares, compared to its average volume of 62,208. The stock’s 50-day simple moving average is $10.33 and its 200 day simple moving average is $19.89. Anbio Biotechnology has a twelve month low of $6.61 and a twelve month high of $51.33.

About Anbio Biotechnology

Anbio Biotechnology is dedicated to the advancement of medical technology and the provision of in vitro diagnostics (IVD) products. Our unwavering commitment lies in transforming the diagnostics landscape on a global scale, fostering a paradigm shift towards personalized and decentralized diagnostic solutions. By doing so, we aim to significantly enhance patient prognosis and contribute to the betterment of healthcare worldwide. At Anbio Biotechnology, our extensive portfolio comprises an array of IVD products designed to cater to diverse diagnostic needs.